Michele Janis Appointed Appearing Chief Monetary Officer
Anthony Krick Appointed Vice President & Chief Accounting Officer
YARDLEY, Pa., June 03, 2022 (GLOBE NEWSWIRE) — OptiNose AS (NASDAQ:OPTN), a pharmaceutical firm targeted on sufferers handled by ear, nostril and throat (ENT) and allergy specialists, as we speak introduced that Keith A. Goldan, Chief Monetary Officer, will go away Optinose to simply accept a CFO alternative at one other public firm. Mr. Goldan will proceed to function Chief Monetary Officer till his departure on June 10, 2022.
Chief Govt Officer Peter Miller said, “On behalf of our total staff, I want to thank Keith for his dedication and contributions to Optinose. His management made beneficial contributions to Optinose as we efficiently transitioned from being a non-public, improvement stage firm to being a public, industrial stage firm. And notably, he leaves us with the robust staff of proficient and succesful finance and accounting professionals that he constructed.”
Michele Janis, Vice President of Finance, who joined Optinose in 2011, has served as a member of the Firm’s management staff since becoming a member of Optinose and can now function the Firm’s Appearing Chief Monetary Officer. Anthony Krick, Vice President, Controller, will assume the newly created position of Vice President and Chief Accounting Officer and be accountable for monetary reporting and managing the day to-day actions of the finance & accounting staff. Jonathan Neely, Vice President, Investor Relations & Enterprise Improvement will lead investor communications. He and Mr. Krick may also be part of the Firm’s management staff.
“It’s been a privilege to function the Optinose CFO and to have labored with such an exceptionally proficient staff,” stated Keith Goldan, departing Chief Monetary Officer.
About Optinose
Optinose is a specialty pharmaceutical firm targeted on serving the wants of sufferers cared for by ear, nostril and throat (ENT) and allergy specialists. Optinose has workplaces within the U.S. and Norway. To be taught extra, please go to www.optinose.com or observe us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
